Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Panobinostat in Combination with Rituximab in Heavily Pretreated Diffuse Large B-Cell Lymphoma: Results of a Phase II Study

Jeffrey A. Barnes, MD PhD, Robert Allyn Redd, MS, Eric D. Jacobsen, MD, David C. Fisher, MD, Arnold S. Freedman, MD, Ephraim P Hochberg, MD, Tak Takvorian, MD, Donna Neuberg, ScD, Jeremy S. Abramson, MD

Blood (2014) 124 (21): 3055.

https://doi.org/10.1182/blood.V124.21.3055.3055

Published: 2014

Journal Articles

Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphomas: Final Results from a Phase 1-2 Trial

Jeremy S. Abramson, MD, Eric D. Jacobsen, MD, Robert Allyn Redd, MS, Tak Takvorian, MD, David C. Fisher, MD, Jennifer R. Brown, Joel H Schwartz, MD, James Weitzman, MD, Donna Neuberg, ScD, Jeffrey A. Barnes, MD PhD, Ephraim P Hochberg, MD

Blood (2014) 124 (21): 4423.

https://doi.org/10.1182/blood.V124.21.4423.4423

Published: 2014

Journal Articles

Ofatumumab As Initial Therapy For Indolent B Cell Lymphomas: A Phase II Trial

Jeffrey A. Barnes, MD, PhD, Yang Feng, PhD, Ephraim P Hochberg, MD, Tak Takvorian, MD, James Weitzman, MD, David C. Fisher, MD, Eric D. Jacobsen, MD, Robin Joyce, MD, Donna S. Neuberg, ScD, Jeremy S. Abramson, MD

Blood (2013) 122 (21): 3062.

https://doi.org/10.1182/blood.V122.21.3062.3062

Published: 2013

Journal Articles

Double Hit Lymphomas: Evaluation of Prognostic Factors and Impact of Therapy

Jeremy S. Abramson, MD, Jeffrey A. Barnes, MD, PhD, Yang Feng, PhD, Tak Takvorian, MD, Donna S. Neuberg, ScD, Ephraim P. Hochberg, MD, Aliyah R. Sohani, MD

Blood (2012) 120 (21): 1619.

https://doi.org/10.1182/blood.V120.21.1619.1619

Published: 2012

Journal Articles

Increased Dose Rituximab Followed by Maintenance Rituximab As Initial Therapy for Indolent B Cell Lymphomas: A Phase II Trial,

Jeffrey A. Barnes, MD, PhD, Kristen Stevenson, Ephraim P. Hochberg, MD, Tak Takvorian, MD, David C. Fisher, MD, Ann LaCasce, MD, Jennifer R. Brown, MD, PhD, Anuj K. Mahindra, MD, Donna Neuberg, ScD, Jeremy S. Abramson, MD

Blood (2011) 118 (21): 3716.

https://doi.org/10.1182/blood.V118.21.3716.3716

Published: 2011

Journal Articles

High Rate of Initial Treatment Failure in Patients with Primary Mediastinal B-Cell Lymphoma Treated with R-CHOP

Jeremy S. Abramson, MD, Matthew D Hellmann, MD, Yang Feng, PhD, Jeffrey A. Barnes, MD, PhD, Tak Takvorian, MD, Christiana E. Toomey, Michael Sheppard, James S. Michaelson, PhD, Donna Neuberg, ScD, Ephraim P. Hochberg, MD

Blood (2011) 118 (21): 1601.

https://doi.org/10.1182/blood.V118.21.1601.1601

Published: 2011

Journal Articles

A Phase I Dose-Escalation Trial of Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma

Jeremy S Abramson, MD, Tak Takvorian, MD, Eric D Jacobsen, MD, Jennifer R Brown, MD, PhD, Jeffrey A. Barnes, MD, PhD, Yang Feng, Donna Neuberg, ScD, Ephraim P. Hochberg, MD

Blood (2010) 116 (21): 1775.

https://doi.org/10.1182/blood.V116.21.1775.1775

Published: 2010

Journal Articles

Rituximab Added to CODOX-M/IVAC Is Highly Effective in HIV-Negative and hiv-Positive Burkitt Lymphoma

Jeremy S. Abramson, MD, Jeffrey A. Barnes, M.D., Christiana E. Toomey, Eric D. Jacobsen, MD, Philippe Armand, Tak Takvorian, MD, David C. Fisher, MD, Hazel Reynolds, Ephraim P. Hochberg, Ann S. LaCasce, MD

Blood (2008) 112 (11): 3595.

https://doi.org/10.1182/blood.V112.11.3595.3595

Published: 2008

Journal Articles

High False Positive Rate with the Use of CT and FDG-PET in Post-Remission Surveillance for Hodgkin Lymphoma.

Dan Zuckerman, MD, Ann Lacasce, MD, Eric Jacobsen, MD, Tak Takvorian, MD, Ephraim Hochberg, MD

Blood (2007) 110 (11): 2327.

https://doi.org/10.1182/blood.V110.11.2327.2327

Published: 2007

Journal Articles

Intermediate Dose Intravenous Methotrexate (MTX) Dramatically Reduces the Risk of Secondary Central Nervous System (CNS) Lymphoma.

Ephraim P. Hochberg, MD, Peter Hammerman, MD, Tak Takvorian, MD, Christiana Toomey, James Michaelson, PhD, Aliyah Rahemtullah, MD, Jeremy S. Abramson, MD

Blood (2007) 110 (11): 3442.

https://doi.org/10.1182/blood.V110.11.3442.3442

Published: 2007

NARROW

Panobinostat in Combination with Rituximab in Heavily Pretreated Diffuse Large B-Cell Lymphoma: Results of a Phase II Study

Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphomas: Final Results from a Phase 1-2 Trial

Ofatumumab As Initial Therapy For Indolent B Cell Lymphomas: A Phase II Trial

Double Hit Lymphomas: Evaluation of Prognostic Factors and Impact of Therapy

Increased Dose Rituximab Followed by Maintenance Rituximab As Initial Therapy for Indolent B Cell Lymphomas: A Phase II Trial,

High Rate of Initial Treatment Failure in Patients with Primary Mediastinal B-Cell Lymphoma Treated with R-CHOP

A Phase I Dose-Escalation Trial of Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma

Rituximab Added to CODOX-M/IVAC Is Highly Effective in HIV-Negative and hiv-Positive Burkitt Lymphoma

High False Positive Rate with the Use of CT and FDG-PET in Post-Remission Surveillance for Hodgkin Lymphoma.

Intermediate Dose Intravenous Methotrexate (MTX) Dramatically Reduces the Risk of Secondary Central Nervous System (CNS) Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only